Assessment of safety, tolerability and effectiveness of adjunctive aripiprazole to lithium/valproate in bipolar mania: a 46-week, open-label extension following a 6-week double-blind study

References

• Muller-Oerlinghausen B, Berghofer A, Bauer M. Bipolar disorder. Lancet 2002;19;359:241-7
   Web of Science ®Google Scholar
• Grunze H, Kasper S, Goodwin G, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders, part III: maintenance treatment. World J Biol Psychiatry 2004;5:120-35
   PubMed Web of Science ®Google Scholar
• Suppes T, Dennehy EB, Hirschfeld RM, et al. The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J Clin Psychiatry 2005;66:870-86
   PubMed Web of Science ®Google Scholar
• Perlis RH, Keck PE. The Texas implementation of medication algorithms update for treatment of bipolar I disorder. J Clin Psychiatry 2005;66:818-20
   PubMed Web of Science ®Google Scholar
• Vieta E, Goikolea JM. Atypical antipsychotics: newer options for mania and maintenance therapy. Bipolar Disord 2005;7(Suppl. 4):21-33
   PubMed Web of Science ®Google Scholar
• APA. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002;159(4 Suppl.):1-50
   Web of Science ®Google Scholar
• Tohen M, Chengappa KN, Suppes T, et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry 2002;59:62-9
   PubMed Web of Science ®Google Scholar
• Sachs GS, Grossman F, Ghaemi SN, et al. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Am J Psych 2002;159:1146-54
   PubMed Web of Science ®Google Scholar
• Yatham LN, Grossman F, Augustyns I, et al. Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial. Br J Psychiatry 2003;182:141-7
   PubMed Web of Science ®Google Scholar
• Sachs G, Chengappa KN, Suppes T, et al. Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study. Bipolar Disord 2004;6:213-23
   PubMed Web of Science ®Google Scholar
• Yatham LN, Vieta E, Young AH, et al. A double blind, randomized, placebo-controlled trial of quetiapine as an add-on therapy to lithium or divalproex for the treatment of bipolar mania. Int Clin Psychopharmacol 2007;22:212-20
   PubMed Web of Science ®Google Scholar
• Yatham LN, Paulsson B, Mullen J, et al. Quetiapine versus placebo in combination with lithium or divalproex for the treatment of bipolar mania. J Clin Psychopharmacol 2004;24:599-606; erratum in J Clin Psychopharmacol 2005;25:103, 201
   PubMed Web of Science ®Google Scholar
• Vieta E, T'joen C, McQuade RD, et al. Adjunctive aripiprazole in bipolar mania partially non-responsive to valproate/lithium: a placebo-controlled study (CN138-134). Am J Psych 2008;165:1316-25
   PubMed Web of Science ®Google Scholar
• Vieta E, Suppes T, Eggens I, et al. Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). J Affect Disord 2008;109:251-63
   PubMed Web of Science ®Google Scholar
• Suppes T, Vieta E, Liu S, et al. Maintenance treatment for patients with bipolar I disorder: results from a North American study of quetiapine in combination with lithium or divalproex (Trial 127). Am J Psychiatry 2009;16;166:476-88
   Web of Science ®Google Scholar
• Tohen M, Chengappa KN, Suppes T, et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br J Psychiatry 2004;184:337-45
   PubMed Web of Science ®Google Scholar
• Vieta E, Bowden C, Ice K, et al. A 6-month, randomized, placebo-controlled, double blind trial of ziprasidone plus mood stabilizer in subjects with bipolar I disorder. European Psychiatry 2009;24(Suppl. 1):S594
   Web of Science ®Google Scholar
• Shapiro DA, Renock S, Arrington E, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacol 2003;28:1400-11
   PubMed Web of Science ®Google Scholar
• Tadori Y, Forbes RA, McQuade RD, et al. Characterization of aripiprazole partial agonist activity at human dopamine D(3) receptors. Eur J Pharmacol 2008;20;597(1-3):27-33
   Web of Science ®Google Scholar
• Jordan S, Koprivica V, Dunn R, et al. In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function. Eur J Pharmacol 2004;483:45-53
   Google Scholar
• Jordan S, Koprivica V, Chen R, et al. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT(1A) receptor. Eur J Pharmacol 2002;26:137-40
   Google Scholar
• Keck PE, Calabrese JR, McQuade RD, et al. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry 2006;67:626-37
   PubMed Web of Science ®Google Scholar
• Keck PE, Calabrese JR, McIntyre RS, et al. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J Clin Psychiatry 2007;68:1480-91
   PubMed Web of Science ®Google Scholar
• Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978;133:429-35
   PubMed Web of Science ®Google Scholar
• Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970;212:11-19
   PubMedGoogle Scholar
• Guy W. Abnormal Involuntary Movement Scale (AIMS). ECDEU Assessment Manual for Psychopharmacology US Department of Health, Education, and Welfare publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health, 1976:534-7
   Google Scholar
• Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989;154:672-6
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-9
   PubMed Web of Science ®Google Scholar
• Leon AC, Solomon DA, Mueller TI, et al. A brief assessment of psychosocial functioning of subjects with bipolar I disorder: the LIFE-RIFT. Longitudinal Interval Follow-up Evaluation-Range Impaired Functioning Tool. J Nerv Ment Dis 2000;188:805-12
   PubMed Web of Science ®Google Scholar
• Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83
   PubMed Web of Science ®Google Scholar
• Torrent C, Amann B, Sanchez-Moreno J, et al. Weight gain in bipolar disorder: pharmacological treatment as a contributing factor. Acta Psychiatr Scand 2008;118:4-18
   PubMed Web of Science ®Google Scholar
• Haddad PM, Das A, Ashfaq M, et al. A review of valproate in psychiatric practice. Expert Opin Drug Metab Toxicol 2009;5:539-51
   PubMed Web of Science ®Google Scholar
• Grandjean EM, Aubry JM. Lithium: updated human knowledge using an evidence-based approach: part III: clinical safety. CNS Drugs 2009;23:397-418
   PubMed Web of Science ®Google Scholar
• Taylor D, Paton C, Kerwin R. The Maudsley Prescribing Guidelines, 9th edn. London: Informa Healthcare, 2007
   Google Scholar
• Correll CU. Balancing efficacy and safety in the treatment with antipsychotics. CNS Drugs 2007;10(Suppl. 17):12-20,35
   Google Scholar
• Correll CU. Acute and long-term adverse effects of antipsychotics. CNS Spectr 2007;12(12 Suppl. 21):10-14
   PubMed Web of Science ®Google Scholar
• Fleischhacker W, McQuade R, Marcus R, et al. A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia. Biol Psychiatry 2009:65:510-7
   Google Scholar
• Wildes JE, Marcus MD, Fagiolini A. Obesity in patients with bipolar disorder: a biopsychosocial–behavioral model. J Clin Psychiatry 2006;67:904-15
   PubMed Web of Science ®Google Scholar
• Sachs G, Bowden C, Calabrese JR, et al. Effects of lamotrigine and lithium on body weight during maintenance treatment of bipolar I disorder. Bipolar Disord 2006;8:175-81
   PubMed Web of Science ®Google Scholar
• Allison DB, Newcomer JW, Dunn AL, et al. Obesity among those with mental disorders: a National Institute of Mental Health meeting report. Am J Prev Med 2009;36:341-50
   PubMed Web of Science ®Google Scholar
• Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005;19(Suppl. 1):1-93
   PubMed Web of Science ®Google Scholar
• Goldstein BI, Fagiolini A, Houck P, et al. Cardiovascular disease and hypertension among adults with bipolar I disorder in the United States. Bipolar Disord 2009;11:657-62
   PubMed Web of Science ®Google Scholar
• McElroy SL, Kotwal R, Malhotra S, et al. Are mood disorders and obesity related? A review for the mental health professional. J Clin Psychiatry 2004;65:634-51, quiz 730
   PubMed Web of Science ®Google Scholar
• Fagiolini A, Frank E, Scott JA, et al. Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disord 2005;7:424-30
   PubMed Web of Science ®Google Scholar
• De Hert M, Dekker JM, Wood D, et al. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry 2009;24:412-24
   Google Scholar
• Ramaswamy K, Markowitz JS, Engelhart MA. Sedation, quality of life, and functioning in bipolar patients prescribed risperidone, quetiapine, or olanzapine. American Psychiatric Association Annual Meeting, Atlanta, GA, May 21–26 2005
   Google Scholar
• Kane JM, Sharif ZA. Atypical antipsychotics: sedation versus efficacy. J Clin Psychiatry 2008;69(Suppl. 1):18-31
   PubMed Web of Science ®Google Scholar
• Said Q, Gutterman EM, Kim MS, et al. Somnolence effects of antipsychotic medications and the risk of unintentional injury. Pharmacoepidemiol Drug Saf 2008;17:354-64
   PubMed Web of Science ®Google Scholar
• Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002;59:530-7
   PubMed Web of Science ®Google Scholar
• Sanchez-Moreno J, Martinez-Aran A, Tabares-Seisdedos R, et al. Functioning and disability in bipolar disorder: an extensive review. Psychother Psychosom 2009;78:285-97
   PubMed Web of Science ®Google Scholar
• Bowden CL, Vieta E, Ice KS, et al. Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial. J Clin Psychiatry 2010;71:130-7
   Google Scholar
• Suppes T, Vieta E, Liu S, et al. Maintenance treatment for patients with bipolar I disorder: results from a North American study of quetiapine in combination with lithium or divalproex (trial 127). Am J Psychiatry 2009;166:476-88
   PubMed Web of Science ®Google Scholar
• Taylor GJ, Wainwright P. Open label extension studies: research or marketing?. BMJ 2005 10;331:572-4
   Google Scholar
• Goodwin G, Fleischhacker W, Arango C, et al. Advantages and disadvantages of combination treatment with antipsychotics. ECNP Consensus Meeting, March 2008, Nice. Eur Neuropsychopharmacol 2009;19:520-32
   Google Scholar